Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of the Dosage of Asymmetric Dimethylarginine (ADMA) Plasma in the Assessment of Endothelial Dysfunction During Growth Hormone Deficiency and Intrauterine Growth Retardation

NCT03422081 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT03422081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of the Dosage of Asymmetric Dimethylarginine (ADMA) Plasma in the Assessment of Endothelial Dysfunction During Growth Hormone Deficiency and Intrauterine Growth Retardation
Lead sponsor
University Hospital, Lille
Phase
Observational
Overall status
Completed
Start date
June 30, 2014
Completion date
December 31, 2018
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency, small-for-gestational age